Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The event is scheduled for September 9-11, 2024. Ted White, President and CEO of Verrica, will engage in a fireside chat on Monday, September 9, 2024, at 1:30 pm ET.

Interested parties can access a live webcast of the event through a provided link or via the Investors/Presentations & Events section of Verrica's website. A replay of the webcast will be available for 90 days following the event, offering extended access to those unable to attend live.

WEST CHESTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the H.C. Wainwright 26^th Annual Global Investment Conference in New York City.

H.C. Wainwright 26^th Annual Global Investment Conference, September 9-11, 2024.
Event details:
Date: Monday, September 9, 2024
Time: 1:30 pm ET
Location: New York, NY

Participants may access a live webcast of the event by clicking the link here.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Verrica Pharmaceuticals Inc. 
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:
Investors:

Terry Kohler 
Chief Financial Officer 
tkohler@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

Chris Calabrese 
LifeSci Advisors 
ccalabrese@lifesciadvisors.com

FAQ

When is Verrica Pharmaceuticals (VRCA) participating in the H.C. Wainwright Global Investment Conference?

Verrica Pharmaceuticals (VRCA) is participating in the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 1:30 pm ET in New York City.

Who will represent Verrica Pharmaceuticals (VRCA) at the H.C. Wainwright conference?

Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will represent the company in a fireside chat at the H.C. Wainwright conference.

How can investors access Verrica Pharmaceuticals' (VRCA) presentation at the H.C. Wainwright conference?

Investors can access a live webcast of Verrica Pharmaceuticals' presentation through a provided link or via the Investors/Presentations & Events section of Verrica's website at www.verrica.com.

How long will the replay of Verrica Pharmaceuticals' (VRCA) presentation be available?

The replay of Verrica Pharmaceuticals' presentation at the H.C. Wainwright conference will be available for 90 days following the event.